ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes could result in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
ZENTALIS PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2014-12-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.zentalis.com
Total Employee:
101+
Status:
Active
Contact:
212-433-3791
Total Funding:
896.6 M USD
Technology used in webpage:
Amazon CrUX Top 50m Amazon S3 Cox Communications
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Board_member
2022-05-01
Board_member
2022-01-01
Board_member
2021-02-01
Current Employees Featured
Kimberly Blackwell Chief Executive Officer @ Zentalis Pharmaceuticals
Chief Executive Officer
2022-05-01
Kevin Bunker Chief Scientific Officer @ Zentalis Pharmaceuticals
Chief Scientific Officer
2022-09-01
Dimitris Voliotis Senior Vice President and Global Head of Clinical Development @ Zentalis Pharmaceuticals
Senior Vice President and Global Head of Clinical Development
2020-03-01
Carrie Brownstein Chief Medical Officer @ Zentalis Pharmaceuticals
Chief Medical Officer
2022-01-01
Mark Lackner Chief Translational Officer, Head of Biomarker Strategy @ Zentalis Pharmaceuticals
Chief Translational Officer, Head of Biomarker Strategy
2022-10-01
Founder
Stock Details
Investors List
Pfizer
Pfizer investment in Post-IPO Equity - Zentalis Pharmaceuticals
Redmile Group
Redmile Group investment in Series C - Zentalis Pharmaceuticals
Viking Global Investors
Viking Global Investors investment in Series C - Zentalis Pharmaceuticals
Eventide
Eventide investment in Series C - Zentalis Pharmaceuticals
Matrix Capital
Matrix Capital investment in Series C - Zentalis Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series C - Zentalis Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Series C - Zentalis Pharmaceuticals
Matrix Capital
Matrix Capital investment in Series B - Zentalis Pharmaceuticals
Viking Global Investors
Viking Global Investors investment in Series B - Zentalis Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.zentalis.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.71 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Zentalis Pharmaceuticals"
Zentalis Pharmaceuticals - Crunchbase Company Profile & Funding
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. …See details»
Zentalis Pharmaceuticals
About Zentalis. Improving Patient lives. We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. …See details»
IR Home - zentalis.com
Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting …See details»
Press Release Distribution and Management - GlobeNewswire
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically …See details»
Zentalis Pharmaceuticals Announces Executive Leadership …
Nov 13, 2024 About Zentalis Pharmaceuticals Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small …See details»
Zentalis Pharmaceuticals - Funding, Financials, Valuation & Investors
Zentalis Pharmaceuticals is registered under the ticker NASDAQ:ZNTL . Their stock opened with $18.00 in its Apr 3, 2020 IPO. Zentalis Pharmaceuticals is funded by 7 investors. Pfizer and …See details»
Zentalis Pharmaceuticals, Inc. (ZNTL) - Yahoo Finance Canada
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. …See details»
Zentalis Pharmaceuticals - Contacts, Employees, Board Members, …
Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients. New. ... Experience the new Crunchbase, powered by AI . Experience the new …See details»
Zentalis Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Zentalis Pharmaceuticals, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
SEC Filing | Zentalis Pharmaceuticals
Mar 15, 2025 Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for …See details»
Document - SEC.gov
SAN DIEGO — January 28, 2025 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small …See details»
Zentalis Pharmaceuticals - Company Profile & Staff Directory
51-200 employees View all Zentalis Pharmaceuticals employees. Industry: Biotechnology Location: 530 Seventh Avenue, Suite 2201, New York, NY 10018, US Get verified email of …See details»
Zentalis Pharmaceuticals Presents Updated Clinical Data at the …
6 days ago ZENTALIS PHARMACEUTICALS. Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with …See details»
Zentalis Pharmaceuticals Announces Inducement Grants Under …
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and …See details»
Zentalis Pharmaceuticals Presents Updated Clinical Data at
6 days ago Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for …See details»
SEC Filing | Zentalis Pharmaceuticals
Of incorporation or organization) ... Zentalis Pharmaceuticals, LLC Condensed Consolidated Statement of Operations (Unaudited) (In thousands, except per unit amounts) Three Months …See details»
Zentalis Pharmaceuticals Announces Workforce Reduction and
Jan 28, 2025 Zentalis Pharmaceuticals announced a restructuring to extend its cash runway into late 2027, following a planned 40% workforce reduction, in preparation for the potentially …See details»
Events & Presentations - Zentalis Pharmaceuticals
IR@zentalis.com. Corporate Presentation. Corporate Presentation – February 2025. Upcoming Events. There are no upcoming events available at this time. Past Events. Mar 10, 2025 9:20 …See details»
Zentalis Pharmaceuticals Announces Multiple Data Presentations …
Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients …See details»
Zentalis Pharmaceuticals Inc. (ZNTL) - Value Research
3 days ago Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various …See details»